- Home
- GOVX vs MDRR Comparison
GOVX vs MDRR Comparison
Compare GOVX & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- MDRR
- Stock Information
- Founded
- GOVX 2001
- MDRR 2015
- Country
- GOVX United States
- MDRR United States
- Employees
- GOVX N/A
- MDRR N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- MDRR Real Estate Investment Trusts
- Sector
- GOVX Health Care
- MDRR Real Estate
- Exchange
- GOVX Nasdaq
- MDRR Nasdaq
- Market Cap
- GOVX 15.5M
- MDRR 15.6M
- IPO Year
- GOVX N/A
- MDRR 2018
- Fundamental
- Price
- GOVX $0.49
- MDRR $10.75
- Analyst Decision
- GOVX Strong Buy
- MDRR
- Analyst Count
- GOVX 5
- MDRR 0
- Target Price
- GOVX $12.40
- MDRR N/A
- AVG Volume (30 Days)
- GOVX 2.4M
- MDRR 1.9K
- Earning Date
- GOVX 08-05-2025
- MDRR 08-08-2025
- Dividend Yield
- GOVX N/A
- MDRR 2.46%
- EPS Growth
- GOVX N/A
- MDRR N/A
- EPS
- GOVX N/A
- MDRR N/A
- Revenue
- GOVX $5,591,576.00
- MDRR $9,485,128.00
- Revenue This Year
- GOVX N/A
- MDRR N/A
- Revenue Next Year
- GOVX N/A
- MDRR N/A
- P/E Ratio
- GOVX N/A
- MDRR N/A
- Revenue Growth
- GOVX N/A
- MDRR N/A
- 52 Week Low
- GOVX $0.43
- MDRR $9.55
- 52 Week High
- GOVX $11.18
- MDRR $15.00
- Technical
- Relative Strength Index (RSI)
- GOVX 29.07
- MDRR 37.34
- Support Level
- GOVX $0.85
- MDRR $9.55
- Resistance Level
- GOVX $0.98
- MDRR $11.04
- Average True Range (ATR)
- GOVX 0.15
- MDRR 0.30
- MACD
- GOVX -0.04
- MDRR -0.09
- Stochastic Oscillator
- GOVX 5.54
- MDRR 51.28
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.